Breathe Well Live Well
|
Approval given for SkyePharma's asthma treatment
Stock Market Wire StockMarketWire.com – SkyePharma (LSE SKP) has announced that the UK regulatory authority, the Medicines and Healthcare product Regulatory Agency (MHRA), has granted marketing authorisation for flutiform®, a combination product for the treatment of … SKYEPHARMA PLC : Half Yearly Report |
View full post on asthma – Google News
|
SkyePharma's Asthma Drug Finally Approved in Europe
Equities.com LONDON – The asthma treatment Flutiform finally won the seal of the European Commission last week, more than 12 years after SkyePharma plc set its sights on what it thought would be the relatively straightforward development of a combination product … Small caps: Drug OK lifts SkyePharma |
View full post on asthma – Google News
|
SkyePharma's asthma drug gets European marketing nod
Reuters Company sees launching drug across Europe in H2* Stock up 28 pct, top percentage gainer on LSEJuly 3 (Reuters) – Britain's SkyePharma Plc said itsasthma therapy Flutiform got marketing approval from. |
View full post on asthma – Google News
|
SkyePharma's asthma drug wins European backing
Reuters UK LONDON (Reuters) – British pharmaceutical company SkyePharma said on Friday its asthma therapy Flutiform had been recommended for approval by European regulators, sending its shares soaring. Flutiform was referred to the European Medicines Agency (EMA) … |
View full post on asthma – Google News
|
New year brings new delay for SkyePharma's Flutiform asthma inhaler
FierceDrugDelivery That's because the British drug delivery company now stands to face an additional delay of between 6 and 9 months in the approval process for its Flutiform asthma therapy. As Reuters and the UK's The Telegraph reported just before the holidays, … |
View full post on asthma – Google News
|
SkyePharma's Asthma Treatment Faces European Approval Delay; Shares Fall
RTT News PK: News ) plunged on the London Stock Exchange in Tuesday morning trade, after the British drug delivery specialist reported a delay in review of the European Marketing Authorisation Application or MAA for its asthma therapy Flutiform due to lack of … SkyePharma lung drug faces European approval delay |
View full post on asthma – Google News